MgShell

Milan, Italy

MgShell manufactures intraocular devices for treating exudative form of age-related macular degeneration.

$1.3M raised

Apr 2025

Seed

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has MgShell raised?

MgShell has raised $1.3M in total funding. The most recent round was Seed. The last funding was announced in April 2025.

Who are MgShell's investors?

MgShell's investors include Capital Cell, Club degli Investitori, Simon Fiduciaria, PoliHub, Italian Angels for Biotech.

Where is MgShell headquartered?

MgShell is headquartered in Milan, Italy.

What does MgShell do?

MgShell manufactures intraocular devices for treating exudative form of age-related macular degeneration.

What stage is MgShell at?

MgShell is at the Seed stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated April 30, 2025.

MLA

"MgShell — Funding & Investors." VCBacked, April 30, 2025, https://www.vcbacked.co/company/mgshell. Accessed July 1, 2026.

APA

VCBacked. (2025). MgShell — Funding & Investors. Retrieved July 1, 2026, from https://www.vcbacked.co/company/mgshell

Wikipedia (cite web)

{{cite web |title=MgShell — Funding & Investors |url=https://www.vcbacked.co/company/mgshell |website=VCBacked |access-date=July 1, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated April 30, 2025.